Molecular typing relies on molecular genetic testing and isn't yet routinely out there. Molecular subtypes and immunohistochemical surrogate markers from the tumors (HR, HER2, triple unfavorable) correlate in about 70%. The differentiation of luminal A and B subtypes by HR position and proliferation markers like Ki-67 might be valuable, https://leonardoa975wfp4.tokka-blog.com/profile